Aged Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/*pathology Female Humans Immune Checkpoint Inhibitors/*therapeutic use Liver Neoplasms/secondary Male Middle Aged Survival Analysis Urinary Bladder Neoplasms/*drug therapy/*pathology bladder cancer immune checkpoint inhibitors immunotherapy meta-analysis urothelial carcinoma

Aged Aged 80 and over Female Humans Male Middle Aged Neoplasm Recurrence Local/*therapy Rhabdomyosarcoma/mortality/*therapy Survival Analysis Urinary Bladder Neoplasms/mortality/*therapy Adult Bladder Rhabdomyosarcoma

Humans Lymphocytes/*pathology Neutrophils/*pathology *Preoperative Care Prognosis Publication Bias Survival Analysis Urinary Bladder Neoplasms/*immunology/*surgery

Cystectomy/*methods Humans Survival Analysis Urinary Bladder Neoplasms/mortality/*surgery Bladder cancer Delay Radical cystectomy Survival

Antineoplastic Agents Alkylating/pharmacology/*therapeutic use Cyclophosphamide/pharmacology/*therapeutic use Female Humans Male Survival Analysis Urinary Bladder Neoplasms/*drug therapy/mortality Cyclophosphamide Hematuria Systematic review Urinary bladder neoplasms

Biomarkers Tumor/genetics Carcinoma/genetics Gene Expression/genetics Gene Expression Profiling/methods Gene Expression Regulation Neoplastic/genetics Humans Neoplasm Recurrence Local/genetics Odds Ratio Prognosis RNA Circular/*genetics Survival Analysis Transcriptome/genetics Urinary Bladder/pathology Urinary Bladder Neoplasms/*genetics/metabolism bladder cancer circular RNA meta-analysis

Antibodies Monoclonal/adverse effects/therapeutic use Antibodies Monoclonal Humanized/adverse effects/therapeutic use Antineoplastic Agents Immunological/*therapeutic use B7-H1 Antigen/*antagonists & inhibitors Clinical Trials Phase III as Topic Humans Network Meta-Analysis Programmed Cell Death 1 Receptor/*antagonists & inhibitors Salvage Therapy/*methods Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/*secondary PD-1 inhibitor PDL-1 inhibitor atezolizumab pembrolizumab urothelial bladder cancer

B7-H1 Antigen/*metabolism Biomarkers Tumor/metabolism Carcinoma Transitional Cell/metabolism/*mortality/pathology Cell Membrane/metabolism Gene Expression Regulation Neoplastic Humans Neoplasm Staging Prognosis Survival Analysis *Up-Regulation Urinary Bladder Neoplasms/metabolism/*mortality/pathology Biomarker Meta-analysis Pd-l1 Urothelial carcinoma

Carcinoma in Situ/diagnosis/epidemiology/*pathology/surgery *Cystectomy Disease-Free Survival Humans Neoplasm Recurrence Local/*diagnosis/epidemiology/pathology Prognosis Survival Analysis Treatment Outcome Ureteral Neoplasms/*diagnosis/epidemiology/pathology/secondary Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/mortality/*pathology/surgery

Aged Biomarkers Tumor/*blood Cystectomy/*adverse effects Female Humans Leukocyte Count Lymphocytes/*pathology Male Middle Aged Monocytes/*pathology Neoplasm Recurrence Local/blood/*epidemiology Postoperative Complications/blood/*epidemiology Survival Analysis Urinary Bladder Neoplasms/*blood/pathology/surgery

Administration Intravesical Aged Aged 80 and over BCG Vaccine/*therapeutic use Biopsy Needle Disease-Free Survival Female Humans Immunohistochemistry Immunotherapy/*methods In Situ Hybridization Fluorescence Male Middle Aged Neoplasm Recurrence Local/mortality/*pathology Predictive Value of Tests Prognosis Risk Assessment Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/mortality/pathology/*therapy Bcg Bladder cancer Immunotherapy Personalized therapy Response prediction

Age Factors Biomarkers Tumor DNA Methylation/genetics Humans Neoplasm Staging Promoter Regions Genetic Proportional Hazards Models Sex Factors Survival Analysis Tumor Suppressor Proteins/*genetics Urinary Bladder Neoplasms/*genetics/*pathology

*Biomarkers Tumor Disease Progression Gene Expression Humans Matrix Metalloproteinases/*genetics/metabolism Prognosis Publication Bias Survival Analysis Urinary Bladder Neoplasms/*genetics/metabolism/*mortality/pathology bladder cancer matrix metalloproteinases meta-analysis

Anemia/*complications Cystectomy/*methods Female Humans Male Preoperative Period Proportional Hazards Models Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/*surgery Anemia Bladder cancer Hemoglobin Mortality Recurrence

Cation Transport Proteins/*genetics Glutathione Peroxidase/*genetics Humans Neoplasm Recurrence Local/genetics Polymorphism Genetic Survival Analysis Urinary Bladder Neoplasms/genetics/*pathology Glutathione Peroxidase GPX1 Nmibc Nramp1 d534n hGPX1 Pro168Leu meta-analysis recurrence

Aged Aged 80 and over *Biomarkers Tumor Cluster Analysis Cohort Studies Female Gene Expression Profiling Humans Immunohistochemistry Male Middle Aged Mutation Neoplasm Invasiveness Neoplasm Staging Neoplasms Basal Cell/*diagnosis/genetics/*metabolism/mortality Prognosis Survival Analysis Tissue Array Analysis Urinary Bladder Neoplasms/*diagnosis/genetics/*metabolism/mortality Biomarker Bladder cancer

Asian People Biomarkers Tumor Humans Ki-67 Antigen/*immunology Prognosis Proportional Hazards Models Survival Analysis Urinary Bladder Neoplasms/ethnology/*immunology/*mortality White People

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy Adjuvant Cisplatin/administration & dosage *Cystectomy/methods Evidence-Based Medicine Humans *Lymph Node Excision Neoadjuvant Therapy/*methods Neoplasm Invasiveness Organ Sparing Treatments/methods Randomized Controlled Trials as Topic Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/mortality/*pathology/*therapy adjuvant chemotherapy bladder cancer bladder-sparing therapy lymph node dissection neoadjuvant chemotherapy radical cystectomy

Adult Aged Aged 80 and over Biomarkers Tumor/*metabolism Cyclin-Dependent Kinase Inhibitor p16/*metabolism *Down-Regulation Female Gene Expression Regulation Neoplastic Humans Lymphatic Metastasis Male Middle Aged Prognosis Survival Analysis Urinary Bladder Neoplasms/metabolism/mortality/*pathology